The reversibility of the cell cycle arrest, the lack of apoptosis and in vivo toxicity qualified H4R agonists as potential pharmacological tools to protect clonogenic cells from the hematotoxicity of anti-cancer drugs, which remains a major drawback of chemotherapy. The gene discussed is HRH4; the disease is cancer.